Development of a 99mTc-Labeled CXCR4 Antagonist Derivative as a New Tumor Radiotracer-Reference-Cited by-同舟云学术

Development of a 99mTc-Labeled CXCR4 Antagonist Derivative as a New Tumor Radiotracer

Published:2018-02 Issue:1 Volume:33 Page:17-24
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Mikaeili Azadeh¹,Erfani Mostafa²,Shafiei Mohammad²,Kobarfard Farzad³,Abdi Khosrou¹,Sabzevari Omid⁴

Affiliation:

1. Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

2. Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran.

3. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

4. Department of Toxicology and Pharmacology, Faculty of Pharmacy, Toxicology and Poisoning Research Centre, Tehran University of Medical Sciences, Tehran, Iran.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2017.2226

Reference26 articles.

1. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers

2. CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?

3. Chemokine receptors and melanoma metastasis

4. Involvement of chemokine receptors in breast cancer metastasis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation and evaluation of 188Re-labeled octreotide analog in C6 glioma tumor;Journal of Radioanalytical and Nuclear Chemistry;2024-04-17

2. Design of a New ^99mTc-radiolabeled Cyclo-peptide as Promising Molecular Imaging Agent of CXCR₄Receptor: Molecular Docking, Synthesis, Radiolabeling, and Biological Evaluation;Current Radiopharmaceuticals;2023-10-25

3. [99mTc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience;European Journal of Nuclear Medicine and Molecular Imaging;2023-08-19

4. Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy;International Journal of Molecular Sciences;2023-08-03

5. New strategies for a sustainable 99mTc supply to meet increasing medical demands: Promising solutions for current problems;Frontiers in Chemistry;2022-07-22